Expanding presence in Saudi Arabia and UAE with proprietary TriCell and NovaStem platforms
[TechWorld News | Reporter Jisung Park]
Korean biotech firm REV-MED announced its growing presence across key Middle Eastern markets, including Saudi Arabia and the United Arab Emirates (UAE), through its proprietary autologous biologic extraction technology. The company is strengthening its global influence by expanding its market share in these regions.
Leveraging regulatory approvals from both Japan’s PMDA and China’s NMPA, REV-MED has successfully passed stringent medical device approval processes in the Middle East. Products such as TriCell and NovaStem, designed to efficiently isolate and concentrate immune and hematopoietic stem cells from blood, attracted significant attention at Arab Health 2025 in Dubai.
REV-MED is not merely focused on product sales. The company has been actively involved in academic activities and R&D, consistently publishing scientific papers and hosting symposia to reinforce its expertise in regenerative medicine.
The Middle East is considered a “blue ocean” for the pharmaceutical and biotech sectors, supported by high healthcare demand and purchasing power. According to Research and Markets, the Middle East and Africa pharmaceutical market is projected to reach approximately USD 42.4 billion by 2030, growing at an average annual rate of 6.10%.
With this growth potential, REV-MED plans to strengthen collaborations across the region and solidify its leadership position in the global biologic concentration device market.
A REV-MED representative stated,
“We are committed to pioneering new frontiers in regenerative medicine through proprietary technologies and continuous R&D. Using our expansion into the Middle East as a stepping stone, we will continue to scale our business globally.”
Source: TechWorld News
Expanding presence in Saudi Arabia and UAE with proprietary TriCell and NovaStem platforms
[TechWorld News | Reporter Jisung Park]
Korean biotech firm REV-MED announced its growing presence across key Middle Eastern markets, including Saudi Arabia and the United Arab Emirates (UAE), through its proprietary autologous biologic extraction technology. The company is strengthening its global influence by expanding its market share in these regions.
Leveraging regulatory approvals from both Japan’s PMDA and China’s NMPA, REV-MED has successfully passed stringent medical device approval processes in the Middle East. Products such as TriCell and NovaStem, designed to efficiently isolate and concentrate immune and hematopoietic stem cells from blood, attracted significant attention at Arab Health 2025 in Dubai.
REV-MED is not merely focused on product sales. The company has been actively involved in academic activities and R&D, consistently publishing scientific papers and hosting symposia to reinforce its expertise in regenerative medicine.
The Middle East is considered a “blue ocean” for the pharmaceutical and biotech sectors, supported by high healthcare demand and purchasing power. According to Research and Markets, the Middle East and Africa pharmaceutical market is projected to reach approximately USD 42.4 billion by 2030, growing at an average annual rate of 6.10%.
With this growth potential, REV-MED plans to strengthen collaborations across the region and solidify its leadership position in the global biologic concentration device market.
A REV-MED representative stated,
“We are committed to pioneering new frontiers in regenerative medicine through proprietary technologies and continuous R&D. Using our expansion into the Middle East as a stepping stone, we will continue to scale our business globally.”
Source: TechWorld News